-
公开(公告)号：US11660321B2
公开(公告)日：2023-05-30
申请号：US16481643
申请日：2018-01-31
发明人： Dong-Hyun Kim , Myung Joo Han
IPC分类号： A61K35/745 , A23L7/104 , A23L33/135 , A61P37/06 , A61P37/08 , A61P29/00 , C12N1/20 , A21D8/04 , A23C9/127 , A23L2/02 , A23L2/52 , A61K35/747 , C12R1/25 , A61K35/00
CPC分类号： A61K35/745 , A21D8/04 , A23C9/127 , A23L2/02 , A23L2/52 , A23L7/104 , A23L33/135 , A61K35/747 , A61P29/00 , A61P37/06 , A61P37/08 , C12N1/205 , A23V2002/00 , A23Y2220/67 , A23Y2300/55 , A61K2035/115 , C12R2001/25
摘要： A particular Bifidobacterium spp. strain or particular Lactobacillus spp. strain according to the present invention is isolated from excrement of a human or cabbage kimchi, and thus is highly safe and has physiological activities such as an immunity regulatory effect and an inflammation reaction inhibiting effect. Therefore, the particular Bifidobacterium spp. strain or particular Lactobacillus spp. strain according to the present invention may be used as a material for regulating immunity and inhibiting inflammation reactions, and may be also used as a functional food and drug material useful for preventing, alleviating or treating rhinitis, atopy, asthma, etc. which are allergic diseases.
-
公开(公告)号：US20170367360A1
公开(公告)日：2017-12-28
申请号：US15544770
申请日：2016-01-28
CPC分类号： A23C9/1209 , A23C9/1206 , A23C9/123 , A23C9/127 , A23C13/16 , A23C17/02 , C12Y302/01 , C12Y304/17 , C12Y304/21 , C12Y304/24
摘要： The present invention relates to a method of preparing a fermented milk product. The method comprises the steps of treating a milk substrate with a low pH sensitive peptidase and a microorganism, and allowing the treated milk substrate to ferment to produce the fermented milk product.
-
公开(公告)号：US09789140B2
公开(公告)日：2017-10-17
申请号：US15260879
申请日：2016-09-09
申请人： Crestovo LLC
发明人： Thomas Julius Borody
IPC分类号： A61K39/08 , A61K39/00 , A61K39/38 , A61K39/116 , A61K39/09 , A01N63/00 , A01N65/00 , A61K35/742 , A61K35/74 , A61K38/48 , A61K35/741 , A61K35/744 , A61K35/747 , A61K36/062 , A61K45/06 , A61K38/14 , A61K31/341 , A61K31/41 , A61K31/495 , A61K31/7034 , A23L2/52 , A61K35/745 , A61K35/38 , A61K35/24 , A61K9/00 , A23C9/123 , A61K9/48 , A23C9/13 , A23L33/135 , A23C9/127 , A61K9/19 , A61K35/37 , A61K31/545 , A61K35/76 , A61K31/43 , A61K38/00 , A61K31/7048 , A61K9/50 , A61K39/39 , A61K51/12 , A61K35/00
CPC分类号： A61K35/742 , A23C9/123 , A23C9/127 , A23C9/13 , A23L2/52 , A23L33/135 , A23V2002/00 , A61K9/0031 , A61K9/0053 , A61K9/19 , A61K9/48 , A61K9/4891 , A61K9/50 , A61K9/5005 , A61K9/5078 , A61K31/341 , A61K31/41 , A61K31/43 , A61K31/495 , A61K31/545 , A61K31/7034 , A61K31/7048 , A61K35/24 , A61K35/37 , A61K35/38 , A61K35/74 , A61K35/741 , A61K35/744 , A61K35/745 , A61K35/747 , A61K35/76 , A61K36/062 , A61K38/00 , A61K38/14 , A61K38/4893 , A61K39/00 , A61K39/39 , A61K45/06 , A61K51/1217 , A61K2035/115 , C12N2795/00032 , Y02A50/401 , Y02A50/469 , Y02A50/473 , A61K2300/00
摘要： The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.
-
公开(公告)号：US09682108B2
公开(公告)日：2017-06-20
申请号：US15260207
申请日：2016-09-08
申请人： Crestovo LLC
发明人： Thomas Julius Borody
IPC分类号： A01N63/00 , A01N65/00 , A61K39/08 , A61K35/742 , A61K35/74 , A61K38/48 , A61K35/741 , A61K35/744 , A61K35/747 , A61K36/062 , A61K45/06 , A61K38/14 , A61K31/341 , A61K31/41 , A61K31/495 , A61K31/7034 , A23L2/52 , A61K35/745 , A61K35/38 , A61K35/24 , A61K9/00 , A23C9/123 , A61K9/48 , A23C9/13 , A23L33/135 , A23C9/127 , A61K9/19 , A61K35/37 , A61K31/545 , A61K39/00 , A61K35/76 , A61K31/43 , A61K38/00 , A61K31/7048 , A61K9/50 , A61K39/39 , A61K51/12 , A61K35/00
CPC分类号： A61K35/742 , A23C9/123 , A23C9/127 , A23C9/13 , A23L2/52 , A23L33/135 , A23V2002/00 , A61K9/0031 , A61K9/0053 , A61K9/19 , A61K9/48 , A61K9/4891 , A61K9/50 , A61K9/5005 , A61K9/5078 , A61K31/341 , A61K31/41 , A61K31/43 , A61K31/495 , A61K31/545 , A61K31/7034 , A61K31/7048 , A61K35/24 , A61K35/37 , A61K35/38 , A61K35/74 , A61K35/741 , A61K35/744 , A61K35/745 , A61K35/747 , A61K35/76 , A61K36/062 , A61K38/00 , A61K38/14 , A61K38/4893 , A61K39/00 , A61K39/39 , A61K45/06 , A61K51/1217 , A61K2035/115 , C12N2795/00032 , Y02A50/401 , Y02A50/469 , Y02A50/473 , A61K2300/00
摘要： The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.
-
公开(公告)号：US09610308B2
公开(公告)日：2017-04-04
申请号：US15178539
申请日：2016-06-09
申请人： Crestovo LLC
发明人： Thomas Julius Borody
IPC分类号： A61K39/00 , A61K39/38 , A61K39/02 , A61K39/08 , A61K39/108 , A61K35/741 , A61K35/74 , A61K38/48 , A61K35/742 , A61K35/744 , A61K35/747 , A61K36/062 , A61K45/06 , A61K38/14 , A61K31/341 , A61K31/41 , A61K31/495 , A61K31/7034 , A23L2/52 , A61K35/745 , A61K35/38 , A61K35/24 , A61K9/00 , A23C9/123 , A61K9/48 , A23C9/13 , A23L33/135 , A23C9/127 , A61K31/545 , A61K35/76 , A61K31/43 , A61K38/00 , A61K31/7048 , A61K9/50 , A61K39/39 , A61K51/12 , A61K35/00
CPC分类号： A61K35/742 , A23C9/123 , A23C9/127 , A23C9/13 , A23L2/52 , A23L33/135 , A23V2002/00 , A61K9/0031 , A61K9/0053 , A61K9/19 , A61K9/48 , A61K9/4891 , A61K9/50 , A61K9/5005 , A61K9/5078 , A61K31/341 , A61K31/41 , A61K31/43 , A61K31/495 , A61K31/545 , A61K31/7034 , A61K31/7048 , A61K35/24 , A61K35/37 , A61K35/38 , A61K35/74 , A61K35/741 , A61K35/744 , A61K35/745 , A61K35/747 , A61K35/76 , A61K36/062 , A61K38/00 , A61K38/14 , A61K38/4893 , A61K39/00 , A61K39/39 , A61K45/06 , A61K51/1217 , A61K2035/115 , C12N2795/00032 , Y02A50/401 , Y02A50/469 , Y02A50/473 , A61K2300/00
摘要： The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.
-
公开(公告)号：US20160375068A1
公开(公告)日：2016-12-29
申请号：US15260207
申请日：2016-09-08
申请人： Crestovo LLC
发明人： Thomas Julius BORODY
IPC分类号： A61K35/742 , A61K35/37 , A61K35/741 , A61K35/747 , A61K35/745 , A61K9/00 , A61K9/19
CPC分类号： A61K35/742 , A23C9/123 , A23C9/127 , A23C9/13 , A23L2/52 , A23L33/135 , A23V2002/00 , A61K9/0031 , A61K9/0053 , A61K9/19 , A61K9/48 , A61K9/4891 , A61K9/50 , A61K9/5005 , A61K9/5078 , A61K31/341 , A61K31/41 , A61K31/43 , A61K31/495 , A61K31/545 , A61K31/7034 , A61K31/7048 , A61K35/24 , A61K35/37 , A61K35/38 , A61K35/74 , A61K35/741 , A61K35/744 , A61K35/745 , A61K35/747 , A61K35/76 , A61K36/062 , A61K38/00 , A61K38/14 , A61K38/4893 , A61K39/00 , A61K39/39 , A61K45/06 , A61K51/1217 , A61K2035/115 , C12N2795/00032 , Y02A50/401 , Y02A50/469 , Y02A50/473 , A61K2300/00
摘要： The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.
-
公开(公告)号：US20160279178A1
公开(公告)日：2016-09-29
申请号：US15178537
申请日：2016-06-09
申请人： Crestovo LLC
发明人： Thomas Julius BORODY
IPC分类号： A61K35/742 , A61K35/741 , A61K9/48 , A61K9/00
CPC分类号： A61K35/742 , A23C9/123 , A23C9/127 , A23C9/13 , A23L2/52 , A23L33/135 , A23V2002/00 , A61K9/0031 , A61K9/0053 , A61K9/19 , A61K9/48 , A61K9/4891 , A61K9/50 , A61K9/5005 , A61K9/5078 , A61K31/341 , A61K31/41 , A61K31/43 , A61K31/495 , A61K31/545 , A61K31/7034 , A61K31/7048 , A61K35/24 , A61K35/37 , A61K35/38 , A61K35/74 , A61K35/741 , A61K35/744 , A61K35/745 , A61K35/747 , A61K35/76 , A61K36/062 , A61K38/00 , A61K38/14 , A61K38/4893 , A61K39/00 , A61K39/39 , A61K45/06 , A61K51/1217 , A61K2035/115 , C12N2795/00032 , Y02A50/401 , Y02A50/469 , Y02A50/473 , A61K2300/00
摘要： The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.
-
公开(公告)号：US20150306144A1
公开(公告)日：2015-10-29
申请号：US14793630
申请日：2015-07-07
申请人： Thomas Julius BORODY
发明人： Thomas Julius BORODY
IPC分类号： A61K35/24 , A23L1/30 , A61K45/06 , A61K35/745 , A61K35/74 , A61K35/747
CPC分类号： A61K35/742 , A23C9/123 , A23C9/127 , A23C9/13 , A23L2/52 , A23L33/135 , A23V2002/00 , A61K9/0031 , A61K9/0053 , A61K9/19 , A61K9/48 , A61K9/4891 , A61K9/50 , A61K9/5005 , A61K9/5078 , A61K31/341 , A61K31/41 , A61K31/43 , A61K31/495 , A61K31/545 , A61K31/7034 , A61K31/7048 , A61K35/24 , A61K35/37 , A61K35/38 , A61K35/74 , A61K35/741 , A61K35/744 , A61K35/745 , A61K35/747 , A61K35/76 , A61K36/062 , A61K38/00 , A61K38/14 , A61K38/4893 , A61K39/00 , A61K39/39 , A61K45/06 , A61K51/1217 , A61K2035/115 , C12N2795/00032 , Y02A50/401 , Y02A50/469 , Y02A50/473 , A61K2300/00
摘要： The present invention relates to pharmaceutical compositions suitable for the treatment of chronic diseases associated with the presence of abnormal or an abnormal distribution of microflora in the gastrointestinal tract of a mammalian host, which compositions comprise viable non-pathogenic or attenuated pathogenic Clostridia. The compositions further comprise one or more additional viable non-pathogenic or attenuated pathogenic microorganisms selected from the group consisting of Bacteroides, Eubacteria, Fusobacteria, Propionibacteria, Lactobacilli, anaerobic cocci, Ruminococcus, E. coli, Gemmiger, Desulfomonas, Peptostreptococcus, and fungi. The present invention also provides pharmaceutical compositions suitable for the treatment of the same chronic diseases comprising viable non-pathogenic or attenuated pathogenic Escherichia coli, at least one strain of viable non-pathogenic or attenuated pathogenic Bacteroides and at least one strain of viable non-pathogenic or attenuated pathogenic microorganism.
摘要翻译： 本发明涉及适用于治疗与在哺乳动物宿主的胃肠道中存在异常或异常分布的微生物群落有关的慢性疾病的药物组合物，该组合物包含活的非致病性或减毒的病原性梭菌。 所述组合物还包含选自拟杆菌属，真细菌属，细菌杆菌属，丙酸杆菌属，乳杆菌属，厌氧球菌，球菌属，大肠杆菌，Gemmiger，Desulfomonas，消化链球菌和真菌的一种或多种另外的活的非致病或减毒病原微生物。 本发明还提供适用于治疗相同慢性疾病的药物组合物，其包含活的非致病性或减毒致病性大肠杆菌，至少一种活的非致病性或减毒致病性拟杆菌菌株和至少一种存活的非致病性菌株 或减毒病原微生物。
-
公开(公告)号：US20150150298A1
公开(公告)日：2015-06-04
申请号：US14402636
申请日：2013-05-21
IPC分类号： A23L3/3571 , A23K1/00 , A23L3/3463 , A23K3/00 , C12R1/01 , A01N63/00
CPC分类号： A23L3/3571 , A01N63/00 , A23C9/127 , A23K10/18 , A23K30/00 , A23L3/34635 , A23V2002/00 , A23Y2220/63 , A23Y2220/67 , A23Y2220/73 , A23Y2320/00 , A23Y2320/15 , A23Y2320/25 , A23Y2320/39 , C12R1/01
摘要： The present invention relates to novel strains of Propionibacterium as well as preparations and compositions, such as fermentation broths, protective cultures, final food or feed product with Propionibacterium alone or in combination with bacteria of the genus Lactobacillus. The present invention further relates to methods for the controlling of growth of a contaminant, such as a bacteria, yeast or mould by using these novel strains of Propionibacterium.
摘要翻译： 本发明涉及丙酸杆菌的新菌株以及单独的丙酸杆菌或与乳杆菌属细菌组合的制剂和组合物，例如发酵肉汤，保护性培养物，最终食物或饲料产品。 本发明还涉及通过使用这些新型丙酸杆菌菌株来控制污染物如细菌，酵母或霉菌的生长的方法。
-
公开(公告)号：US09011948B2
公开(公告)日：2015-04-21
申请号：US12094541
申请日：2006-11-28
申请人： Petrus Jacobus Theodorus Dekker , Luppo Edens , Maximiliaan Peter Marie De Swaaf , Albertus Alard Van Dijk
发明人： Petrus Jacobus Theodorus Dekker , Luppo Edens , Maximiliaan Peter Marie De Swaaf , Albertus Alard Van Dijk
CPC分类号： A23C9/127 , A23C9/1206 , A23C19/0328 , C12N9/16 , C12N9/2402 , C12N9/2468 , C12N9/2471 , C12N9/62 , C12Y301/06001 , C12Y302/01023 , C12Y302/01108
摘要： Process for producing a dairy product by adding a lactase to a dairy product which contains lactose, the lactase added having less than 40 units arylsulfatase activity per NLU of lactase activity.
摘要翻译： 通过向含有乳糖的乳制品中加入乳糖酶来生产乳制品的方法，所述乳糖酶加入的乳糖酶活性为每NLU少于40个芳基硫酸酯酶活性。
-
-
-
-
-
-
-
-
-
搜索结果
124 条记录 (耗时 0.038 秒)
